The remaining unsolved problems for rational antibiotic therapy use in pediatric community-acquired pneumonia. (4th March 2022)

• Record Type: Journal Article
• Authors: Esposito, Susanna; Argentiero, Alberto; Rebecchi, Francesca; Fainardi, Valentina; Pisi, Giovanna; Principi, Nicola
• Is Part Of: Expert opinion on pharmacotherapy. Volume 23:Number 4(2022)
• Page Start: 497
• Page End: 505
• Publication Date: 2022-03-04
• Subjects: antibiotic therapy -- antimicrobial resistance -- community-acquired pneumonia -- lower respiratory tract infection -- pediatric infectious diseases; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2022.2028773
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Despite availability of several official guidelines, not all the problems related to the most effective and safe use of antibiotics in children with community-acquired pneumonia (CAP) have been solved. Presently, too many children receive unneeded antibiotics or, when antibiotics are mandatory, the choice of the drug is not appropriate. Areas covered: In this paper, the authors discuss the remaining unsolved problems for rational antibiotic therapy use in pediatric community-acquired pneumonia and provide their expert perspectives. Expert opinion: Further improvement in pediatric CAP management could be derived from physician education on antibiotic use and a larger use, particularly in office practice, of point of care testing or new technologies (i.e. artificial intelligence) to define etiology of a lower respiratory infection. However, recommendations regarding the duration of antibiotic therapy vary largely because of the absence of reliable data on the optimal CAP treatment according to the bacterial etiology of the disease, its severity, and child characteristics. Available evidence seems to confirm that a short course of antibiotics, approximately 5 days, can be effective and lead to results not substantially different from those obtained with prolonged-course antibiotic therapy, at least in patients with mild to moderate disease.